Semaglutide, the diabetes and weight loss drug sold as Ozempic and Wegovy, reduces depression and anxiety diagnoses, according to a decade-long study of nearly 100,000 patients. Researchers observed significantly fewer psychiatric hospitalizations and mental health-related sick days among people taking GLP-1 drugs compared to those who did not.
The finding expands the known benefits of these medications beyond metabolic control. GLP-1 receptor agonists work by regulating blood sugar and appetite, but they also influence brain regions tied to mood and reward. Scientists suspect the mental health improvements stem from weight loss itself, improved metabolic health, or direct effects on brain chemistry.
This discovery opens new therapeutic possibilities. Doctors might eventually prescribe these drugs for depression or anxiety, particularly in patients with concurrent metabolic conditions. The results warrant further investigation through controlled trials specifically designed to test mental health outcomes.
Researchers emphasize that these findings are observational, not conclusive proof of causation. Randomized controlled studies will determine whether GLP-1 drugs can serve as psychiatric treatments. The work suggests that medications addressing physical health can simultaneously improve psychological wellbeing, potentially reshaping how clinicians approach treatment.